MedTrace Logo

SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease

NCT06326970 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-03-22

No results posted yet for this study

Summary

This observational study aims to learn about the preliminary exploration of 99mTc-FAPI imaging in heart diseases and its potential application.

Participant involves patients with myocarditis, pulmonary hypertension, arrhythmia, myocardial infarction, dilated cardiomyopathy, and cardiac tumors, health conditions may also studied as control.

The main questions it aims to answer are 1, radionuclide 99mTc labeled fibroblast-activated protein inhibitors (99mTc-FAPI) imaging in the use of cardiac diseases and its limitations. 2, the performance in subjects with different control of hypertension to evaluate myocardial injury and fibrosis for providing a molecular biological basis for the study of diseases and mechanisms.

Participants will undergo 99mTc-FAPI imaging by Single-photon emission computed tomography (SPECT) and record their cardiac disease characterization and treatment.

Conditions

  • Myocardial Fibrosis

Interventions

DIAGNOSTIC_TEST

99mTc-FAPI SPECT imaging

99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.

Sponsors & Collaborators

  • Henan Institute of Cardiovascular Epidemiology

    lead OTHER

Principal Investigators

  • Muwei Li, Ph.D. · Fuwai central China hospital

  • Jing Cui, Ph.D. · Fuwai central China hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2025-03-31
Completion
2025-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326970 on ClinicalTrials.gov